about
Bariatric surgery for diabetes managementSalicylate (salsalate) in patients with type 2 diabetes: a randomized trial.Inhibition of protein kinase Cbeta does not improve endothelial function in type 2 diabetesDiabetes: Bariatric surgery for T2DM--cure, or remission and relapse?Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patientsVisceral adiposity and the risk of metabolic syndrome across body mass index: the MESA StudyGlucagon treatment for post-gastric bypass hypoglycemia.Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.The impact of vitamin D deficiency on diabetes and cardiovascular risk.Diabetes improvement following Roux-en-Y gastric bypass: understanding dynamic changes in insulin secretion and action.How common is hypoglycemia after gastric bypass?Hypoglycemia after gastric bypass: the dark side of GLP-1.New lessons from gastric bypass: Impact of glucose-independent islet function.Changing horizons: approaches to diabetes care, current and future.Type 2 diabetes: new drugs, new perspectives.Plasma ceramides are elevated in female children and adolescents with type 2 diabetes.Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery.The rough road for rosiglitazone.Acute insulin secretion as a predictor of weight gain in healthy humans.Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.Family history of diabetes is a major determinant of endothelial function.Peptide YY levels are elevated after gastric bypass surgery.Statins: Is It Really Time to Reassess Benefits and Risks?Adiponectin: linking the fat cell to insulin sensitivityAssessing the cardiovascular safety of diabetes therapiesCardiovascular safety and diabetes drug developmentExpansion and contraction: treating diabetes with bariatric surgeryFibrates in the treatment of dyslipidemias--time for a reassessmentCardiovascular risk assessment in the development of new drugs for obesityWhere are the health care cost savings with bariatric surgery in obesity management?The rollercoaster of post-bariatric hypoglycaemiaEvaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
P50
Q22242723-EA8CD47B-CE38-40DC-9F4A-DB9FFBF0457FQ34027442-F549AEAC-07AE-48EE-BD09-AFB19FC0B815Q34031989-5AD917AA-197F-4784-BF6F-8EB5BF06B95FQ34162605-7890B021-4829-4458-8131-E9EA08B39D15Q34272841-55890332-98A6-4D70-9307-A7B6F84D1D04Q34715584-9EB7D58B-FB4A-4AD1-8B7B-D43EB3A3AD89Q35738186-7F8048ED-ACAB-4A65-8E95-8B3E4E898C63Q36926364-388362C5-11F0-4752-A6B8-1364AF60133BQ37691189-836269D2-4DFB-4B8A-B4F9-FB41F3327F81Q37715603-4D84F9FB-1D9A-4308-8F12-929A1A0629E0Q41574594-61DE9D1A-7862-4809-AA50-415562BABD28Q42877593-6B3F24ED-BDD4-47DE-97B2-67D47F201DEBQ43237298-74D9256E-7AA9-4621-ABA1-02C15D2CB53AQ43599529-B80F5786-D4A5-45FD-B5D7-1271C88E871AQ43743766-DC590EA1-58E4-4A3E-A3C3-2F6D12819021Q44057275-5726C883-E89D-41CB-BABE-AC6218322BCAQ44548921-194EC2CB-4BB8-4EE9-B2C4-8083A704E102Q46720930-0BD16561-74FF-4392-A6A4-1DB892336739Q46956269-DD82E217-8B11-455A-AC6B-D7E6E83C6FA6Q50233845-039D0D5A-0A2A-470D-93FA-685F4F996E74Q51496361-52EC7C7B-A788-4140-8BD0-0B50875357B8Q51500912-7320DCA8-9527-40ED-A687-44EB6DC68395Q56775292-59E22AA7-AC8E-4EE1-966E-315606A67AA5Q79259455-3FC724D2-820A-4902-895E-5155CA958F82Q81950632-162A0E2E-8048-4964-AEA6-49EB7C415FDFQ83400035-991D77EB-FC70-4F27-BA78-7FCBA6711BCAQ84005737-A2DC3E65-41C5-4919-BB5B-F5E508E995B0Q84737978-5C7AFA0D-7976-43EE-8E9B-5A3584179336Q84992292-0BD6EAA0-A901-4228-965E-DE5E24F200BAQ86654769-199B075A-AA65-4AA8-A03D-91D656052077Q86969104-0AFA32D5-08E3-4D6C-92C7-F63CB5C68EDDQ89253157-5266A74E-ABF2-406C-8FED-5957D7A029E2
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Allison B Goldfine
@ast
Allison B Goldfine
@en
Allison B Goldfine
@es
Allison B Goldfine
@nl
Allison B Goldfine
@sl
type
label
Allison B Goldfine
@ast
Allison B Goldfine
@en
Allison B Goldfine
@es
Allison B Goldfine
@nl
Allison B Goldfine
@sl
prefLabel
Allison B Goldfine
@ast
Allison B Goldfine
@en
Allison B Goldfine
@es
Allison B Goldfine
@nl
Allison B Goldfine
@sl
P106
P21
P31
P496
0000-0002-0345-1048